by The preeclampsia diagnostics market is estimated to be valued at US$ 1587.53 Mn or Mn in 2023 and is expected to exhibit a CAGR of 11.% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Overview:
Preeclampsia is a pregnancy complication characterized by high blood pressure and signs of damage to another organ system, most often the liver and kidneys. It is a leading cause of maternal and fetal illness and death globally. Early diagnosis is key to treating preeclampsia effectively and reducing risks of morbidity and mortality. Preeclampsia diagnostics help in screening, diagnosis, and management of the condition. Products available include instruments, consumables, reagents, and software and services. Rapid diagnosis kits that can detect the condition even in low-resource settings are gaining popularity.
Market Dynamics:
Rising adoption of personalized medicine and companion diagnostics is expected to drive the preeclampsia diagnostics market during the forecast period. Personalized medicine helps in early diagnosis and customizing treatment according to a patient’s genetic makeup and diagnosis. Companion diagnostics aid in identifying which patients are most likely to benefit from a particular therapeutic product. This facilitates optimized clinical outcomes. Moreover, increasing research & development activities for biomarker-based preeclampsia diagnostics is also anticipated to propel market growth. Several organizations are working on identifying novel biomarkers to develop rapid point-of-care tests for early diagnosis of preeclampsia. This is expected to offer lucrative opportunities for market players.
Segment Analysis
The global preeclampsia diagnostics market is segmented on the basis of product & services, test type and end user. Based on product & services, it is segmented into devices, assays & reagents and software & services. The devices segment dominates the market owing to the high usage of instruments like the ultrasound for blood pressure monitoring and edema detection in pregnant women.
PEST Analysis
Political: Regulations regarding preeclampsia screening and surveillance during pregnancy in various countries support market growth.
Economic: Rising healthcare spending and increasing awareness about preeclampsia diagnosis boost the market.
Social: Growing emphasis on women’s healthcare and rising maternal age of first-time pregnancies fuel market expansion.
Technological: Advancements in diagnostic kits, devices and software improve preeclampsia detection and management.
Key Takeaways
The global Preeclampsia Diagnostics Market size is expected to reach US$ 1587.53 Million by 2023, exhibiting a CAGR of 11% during the forecast period. North America dominates the market owing to established healthcare infrastructure and rising cases of preeclampsia. The regional market is expected to generate around 38% of the global revenue by 2023. Key players operating in the preeclampsia diagnostics market are Diabetomics, Inc., Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd, PerkinElmer Inc., Siemens Healthineers AG, DRG INSTRUMENTS GMBH, Metabolomic Diagnostics Ltd., Sera Prognostics, MOMM Diagnostics, and Miraculins Inc. Rising investment in R&D of advanced detection tests and growing awareness among patients are expected to drive the key players to strengthen their regional presence over the forecast period.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
